

**Abstract Number:** [648]

**Abstract Title:** Assessment of Patients' Experiences With Ofatumumab in Multiple Sclerosis: Findings From a Market Research Survey Conducted in the Netherlands

**Abstract Category:** Therapy - 42 - Others

**Preferred Presentation Type:** Oral or poster presentation

Gerald Hengstman\*<sup>1</sup>, Willem Bouvy<sup>2</sup>, Jeroen Van Eijk<sup>3</sup>, Eric Hamers<sup>4</sup>, Mieke Hermans<sup>5</sup>, Floris De Kleermaeker<sup>5</sup>, Michaël Peeters<sup>6</sup>, Luuk Van Rooij<sup>7</sup>, Ronald Van de Ven<sup>2</sup>, Esther Zeinstra<sup>8</sup>

<sup>1</sup>Upendo, Boxtel, Netherlands, <sup>2</sup>Department of Neurology, Diaconessenhuis Utrecht en Zeist, Netherlands, <sup>3</sup>Department of Neurology, Jeroen Bosch Hospital, 's-Hertogenbosch, Netherlands, <sup>4</sup>Novartis Pharma BV, Amsterdam, Netherlands, <sup>5</sup>Department of Neurology, VieCuri Medical Center, Venlo, Netherlands, <sup>6</sup>Department of Neurology, Máxima Medical Center, Eindhoven, Netherlands, <sup>7</sup>Department of Neurology, Maasstad Hospital, Rotterdam, Netherlands, <sup>8</sup>Department of Neurology, Isala Hospital, Meppel, Netherlands

### **Introduction:**

When managing people with multiple sclerosis (MS) on disease-modifying therapies (DMTs), patients' experiences and their treatment satisfaction are important considerations besides the established efficacy and safety of DMTs. Real-world evidence on patients' experiences and satisfaction with ofatumumab (OMB) as a treatment option for relapsing MS is limited.

### **Objectives/Aims:**

To understand real-world patients' experience with OMB treatment and its impact on quality of life in people with MS.

### **Methods:**

A market research survey was conducted by IPSOS in the Netherlands from April 2022 to April 2023 via an online questionnaire. Respondents were recruited via flyers by the specialists in MS centres. The questionnaire was divided into five sections to assess the (1) patient's background characteristics, (2) patient's MS disease history, (3) use of OMB, (4) experience with OMB and (5) impact of OMB on daily life. Survey results were summarised descriptively and categorical variables were summarised using frequencies and percentages.

### **Results:**

As of 25 January 2023, 53 patients (mean age: 51 years; 60% female) completed the survey. All patients were still using OMB at the time of the survey. (1) Most patients live together with others (53%), do not receive additional care at home (68%) and do not work (60%). (2) On average (mean±SD), patients were diagnosed with MS 9.3±6.6 years ago. The mean±SD self-reported Expanded Disability Status Scale (EDSS) score was 4.8±1.5. (3) Patients had been switched to OMB from first- and second-line treatments and relatively often from ocrelizumab (40%). Most patients who switched to OMB had a strong preference for treatment at home (median score: 1, on a Likert scale [1=Home treatment, 5=Hospital treatment]). Patients started taking OMB due to finding it easier to treat their MS at home than at the clinic (n=21), side effects on previous medications (n=19), and disease activity (MRI lesions, relapse, and decline in health; n=20). (4) Over 90% of patients were positive about the OMB user experience in terms of ease of use and administration. (5) OMB was associated with a positive impact on quality of life. Few patients using OMB stated that they don't feel confident (11%), independent (2%), flexible (8%), free (6%) and felt frustrated (2%).

### **Conclusion:**

The results show that people with MS consider monthly at-home subcutaneous treatment with OMB favourable and convenient to use. This positive experience plays an important role in patient satisfaction and treatment adherence in clinical practice.

**Disclosures:** Funding statement: The study was supported by Novartis Pharma BV, Amsterdam, The Netherlands.

Gerald Hengstman gives asked and unasked, paid and unpaid advice to many parties active in the field of MS including: BMS, Biogen, Coloplast, Janssen, Merck, Novartis, Roche and Sanofi.

Willem Bouvy has participated in an advisory board for Novartis.

Jeroen van Eijk has participated in advisory boards and oral presentations for Biogen, Roche, Merck, Genzyme, Novartis, Janssen, BMS.

Eric Hamers is an employee of Novartis.

Mieke Hermans: nothing to disclose

Floris de Kleermaeker: nothing to disclose

Michael Peeters: nothing to disclose

Luuk van Rooij has served as PI for the REMODEL study for Novartis.

Ronald van de Ven: nothing to disclose.

Esther Zeinstra has participated in advisory boards and has nominations for merck, novartis, genzyme and roche.

**Travel / Abstract Grant Application and Young Scientific Investigators' Session:** I will not apply for Travel Grant or Young Scientific Investigators' Session

**Which one would you like to apply to:**

**Date of Birth:**